Skip to main content
. 2014 Sep 23;111(11):2067–2075. doi: 10.1038/bjc.2014.494

Figure 3.

Figure 3

OS (from randomisation) for patients who were randomised to the standard therapy arm (gemcitabine plus erlotinib 100 mg per day) or the dose-escalation arm (gemcitabine plus escalating doses of erlotinib). Abbreviations: HR=hazard ratio; OS=overall survival.